Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Global assessment of partial artemisinin resistance: multicenter trial across Kenya, Peru, and Thailand in patients with uncomplicated Plasmodium falciparum malaria.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2025
Same author

Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force.

The journal of prevention of Alzheimer's disease·2025
Same author

Donanemab: Appropriate use recommendations.

The journal of prevention of Alzheimer's disease·2025
Same author

Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force.

The journal of prevention of Alzheimer's disease·2024
Same author

The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials.

The journal of prevention of Alzheimer's disease·2024
Same author

Burden of Illness in People with Alzheimer's Disease: A Systematic Review of Epidemiology, Comorbidities and Mortality.

The journal of prevention of Alzheimer's disease·2024
Same journal

Drawing a line: Differentiating mild from moderate dementia using the functional activities questionnaire.

The journal of prevention of Alzheimer's disease·2026
Same journal

The generalizability gap: anticoagulant exclusions and the "Enhanced Safety" of donanemab in the EU-eligible population.

The journal of prevention of Alzheimer's disease·2026
Same journal

Asia's dementia burden: from epidemiological description to prevention-oriented neurology.

The journal of prevention of Alzheimer's disease·2026
Same journal

The time interval from amyloid to tau PET positivity varies by age, sex and APOE-ε4 status.

The journal of prevention of Alzheimer's disease·2026
Same journal

Beyond target engagement: RNA therapeutics and the neuroimmune challenge in tauopathies.

The journal of prevention of Alzheimer's disease·2026
Same journal

Tailored implementation of multidomain intervention to prevent cognitive impairment in community-dwelling older adults (Timi-Cog): A study protocol for a hybrid type 2 trial effectiveness-implementation study.

The journal of prevention of Alzheimer's disease·2026
查看所有相关文章

相关实验视频

Updated: Jul 25, 2025

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.4K

莱卡尼马布:适当使用建议

J Cummings1, L Apostolova, G D Rabinovici

  • 1Jeffrey Cummings, MD, ScD, 1380 Opal Valley Street, Henderson, NV 89052, USA, jcummings@cnsinnovations.com, T: 702-902-3939.

The journal of prevention of Alzheimer's disease
|June 25, 2023
PubMed
概括
此摘要是机器生成的。

莱卡内马布 (Leqembi®) 为早期阿尔茨海默病 (AD) 提供了一种新的治疗方法. 这些指导方针有助于医生安全使用这种疗法,考虑到患者与临床试验的差异以及ARIA等潜在风险.

关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.美国食品和药物管理局的食品和药物管理局.加快审批的时间.带来了一些令人惊的东西.粉样蛋白成像成像技术与粉样蛋白相关的成像异常 (ARIA)没有的,没有的,没有的.莱卡内马布 (lecanemab) 是一个磁共振成像 (MRI) 的使用.规定信息的规定信息.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K

相关实验视频

Last Updated: Jul 25, 2025

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.4K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K

科学领域:

  • 神经学 神经学
  • 药理学 药理学是指药理学的学科.
  • 临床实践指南 临床实践指南

背景情况:

  • 莱卡内马布 (Leqembi®) 已被批准用于早期阿尔茨海默氏病 (AD) 的治疗,其中确诊的粉样蛋白病理学.
  • 现实世界的临床实践与临床试验环境不同,需要为社区管理提供具体指导.
  • 现有的2期和3期试验数据为lecanemab的安全性和疗效概况提供了信息.

研究的目的:

  • 为安全有效地将lecanemab引入临床实践提供适当使用建议 (AUR).
  • 指导临床医生在给予lecanemab时,考虑患者群体和不同于临床试验的给药设置.
  • 详细说明与莱卡尼马布治疗相关的潜在不良事件的监测指南.

主要方法:

  • 遵守lecanemab临床试验第二阶段和第三阶段的纳入和排除标准.
  • 将临床试验数据与阿尔茨海默病的更广泛的研究和护理信息进行整合.
  • 制定管理不良事件的协议,包括粉样蛋白相关成像异常 (ARIA) 和输液反应.

主要成果:

  • 莱卡尼马布治疗存在风险,包括ARIA (大多数无症状,有些严重/致命),微出血和大出血.
  • 需要抗凝药的患者建议不要服用lecanemab,直到有进一步的数据,因为增加了出血风险.
  • APOE ε4基因携带者,特别是同胞卵,面临更高的ARIA风险,需要基因定型以进行知情的患者讨论.

结论:

  • 临床和机构的准备,包括严重事件管理的协议,对于lecanemab使用至关重要.
  • 临床医生和患者/护理伙伴之间关于益处,危害和监测的公开沟通是必不可少的.
  • 建立信任和采用文化特定的沟通策略是成功治疗lecanemab的基础.